# Effectiveness and Tolerance of Inhaled Fentanyl Aerosol (25µg/Dose) in Chinese Patients With BTcP

> **NCT05531422** · PHASE2 · COMPLETED · sponsor: **Lee's Pharmaceutical Limited** · enrollment: 60 (actual)

## Conditions studied

- Breakthrough Cancer Pain

## Interventions

- **DRUG:** Inhaled fentanyl aerosol
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05531422
- **Lead sponsor:** Lee's Pharmaceutical Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-20
- **Primary completion:** 2023-03-15
- **Final completion:** 2023-04-27
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2024-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05531422

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05531422, "Effectiveness and Tolerance of Inhaled Fentanyl Aerosol (25µg/Dose) in Chinese Patients With BTcP". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05531422. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*